BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37958610)

  • 1. Resistance to 2-Hydroxy-Flutamide in Prostate Cancer Cells Is Associated with the Downregulation of Phosphatidylcholine Biosynthesis and Epigenetic Modifications.
    Mora-Rodríguez JM; Sánchez BG; Sebastián-Martín A; Díaz-Yuste A; Sánchez-Chapado M; Palacín AM; Sánchez-Rodríguez C; Bort A; Díaz-Laviada I
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L; Levenson AS
    Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP.
    Ravenna L; Lubrano C; Di Silverio F; Vacca A; Felli MP; Maroder M; D'Eramo G; Sciarra F; Frati L; Gulino A
    Prostate; 1995 Jun; 26(6):290-8. PubMed ID: 7784269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells.
    Montalvo L; Carmena MJ; Bolaños O; Rodríguez-Henche N; Sánchez-Chapado M; Prieto JC
    Biosci Rep; 2004 Feb; 24(1):11-21. PubMed ID: 15499829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
    Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
    Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP.
    Warriar N; Pagé N; Koutsilieris M; Govindan MV
    Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening.
    Coe KJ; Jia Y; Ho HK; Rademacher P; Bammler TK; Beyer RP; Farin FM; Woodke L; Plymate SR; Fausto N; Nelson SD
    Chem Res Toxicol; 2007 Sep; 20(9):1277-90. PubMed ID: 17702527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of mutant androgen receptors by flutamide.
    Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
    Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells.
    Kawabata R; Oie S; Oka T; Takahashi M; Kanayama H; Itoh K
    Int J Oncol; 2011 Mar; 38(3):665-76. PubMed ID: 21243325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
    Tong da Y; Wen XQ; Jin Y; Liu ZW; Sun HY; Zhou FJ; Wu XY
    Asian Pac J Cancer Prev; 2010; 11(6):1805-9. PubMed ID: 21338237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
    Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
    Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
    J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
    Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
    Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters.
    Simard J; Singh SM; Labrie F
    Urology; 1997 Apr; 49(4):580-6; discussion 586-9. PubMed ID: 9111629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
    Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
    Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
    Mabjeesh NJ; Willard MT; Frederickson CE; Zhong H; Simons JW
    Clin Cancer Res; 2003 Jul; 9(7):2416-25. PubMed ID: 12855613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.